Ironwood Pharmaceuticals | IRWD - Des Atouts





Des Atouts Changement Date
Acadia Pharmaceuticals USD 1.74B 137.67M 2026-06
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Akebia Therapeutics USD 349.66M 12.86M 2026-06
Almirall EUR 2.37B 29.97M 2026-06
Alnylam Pharmaceuticals USD 5.56B 429.22M 2026-06
Amarin USD 624.36M 21.4M 2026-06
Ardelyx USD 504.51M 2.9M 2026-03
Astellas Pharma JPY 3.69T 125.48B 2026-06
AstraZeneca USD 115.83B 1.82B 2026-06
Charles River Laboratories USD 7.53B 198.16M 2026-06
Coherus Biosciences USD 191.18M 74.84M 2026-06
Emergent BioSolutions USD 1.82B 69.9M 2023-12
Halozyme Therapeutics USD 2.58B 95.31M 2026-06
Incyte USD 7.87B 533.53M 2026-06
Ironwood Pharmaceuticals USD 434.57M 37.66M 2026-03
Karyopharm Therapeutics USD 131.42M 23M 2026-03
Lexicon Pharmaceuticals USD 268.82M 83.83M 2026-03
MacroGenics USD 345.41M 127.54M 2026-06
Moderna USD 10.96B 527M 2026-06
Myriad Genetics USD 638.9M 34.8M 2026-06
Pacira USD 1.24B 35.44M 2026-06
PTC Therapeutics USD 3.25B 381.37M 2026-06
Puma Biotechnology USD 202.86M 7.95M 2025-09
Sarepta Therapeutics USD 3.19B 9.58M 2026-06
Takeda JPY 15.66T 210.16B 2026-06
Ultragenyx Pharmaceutical USD 1.26B 32M 2026-06
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12